The US Preventive Services Task Force (USPSTF) has provided a D recommendation (discourages the use of service) for thyroid cancer screening in asymptomatic individuals.
The US Preventive Services Task Force (USPSTF) has provided a D recommendation (discourages the use of service) for thyroid cancer screening in asymptomatic individuals.
Thyroid cancer incidence has increased nearly 3 times over a 40-year period—15.3 cases per 100,000 in 2013 compared with 4.9 cases per 100,000 in 1975. However, mortality rates have not seen much of a spike: they have increased by 0.7 deaths per 100,000 persons each year. It’s also important to note that the 5-year survival for the disease ranges from 99.9% for localized disease to 55.3% for individuals who have metastases.
The USPSTF revisited neck palpation or ultrasound as a screening technique used in asymptomatic individuals to evaluate its impact on health outcomes. The recommendations, however, do not apply to individuals with hoarseness, pain, difficulty swallowing, or other throat symptoms or persons who have lumps, swelling, asymmetry of the neck, or other reasons for a neck examination. It also does not apply to persons at increased risk of thyroid cancer because of a history of exposure to ionizing radiation, particularly persons with a diet low in iodine, an inherited genetic syndrome associated with thyroid cancer, or a first-degree relative with a history of thyroid cancer.
The USPSTF committee found no direct evidence that compared screened versus unscreened populations or immediate surgery versus surveillance or observation that showed an impact on health outcomes such as mortality, quality of life, or harms.
“The USPSTF found inadequate direct evidence on the harms of screening but determined that the magnitude of the overall harms of screening and treatment can be bounded as at least moderate, given adequate evidence of harms of treatment and indirect evidence that overdiagnosis and overtreatment are likely to be substantial with population-based screening,” the authors noted.
The research need, according to the report, published in JAMA, point to the need for observational studies of early treatment versus surveillance or observation of patients with small, well-differentiated thyroid cancer to identify patients at the highest risk for clinical deterioration. The experts also noted the absence of risk prediction tools or biomarkers to understand the prognosis of differentiated thyroid cancer.
While there is no direct evidence that ascertains that screening for thyroid cancer can result in overdiagnosis, the fact that increased incidence has not resulted in increased mortality is telling, according to the report.
“Overdiagnosis occurs because screening for thyroid cancer often identifies small or slow growing tumors that might never affect a person during their lifetime,” Task Force member Seth Landefeld, MD, said in a statement for USPSTF. “People who are treated for these small tumors are exposed to serious risks from surgery or radiation, but do not receive any real benefit.”
Reference
US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(18):1882-1887. doi: 10.1001/jama.2017.4011.
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More